Strontium-89

04/02/1993 - "A Quality-of-Life analysis was performed as a multivariate data set and demonstrated an overall superiority of strontium-89 with alleviation of pain and improvement in physical activity being statistically significant. "
10/01/2004 - "The efficacy of limited field external radiation in metastatic bone pain palliation was 80.6% versus 58.1% for strontium-89. "
06/01/2005 - "One randomized phase III trial reported no difference in pain relief between strontium-89 and placebo. "
07/01/2009 - "Strontium-89 is not ideal for bone pain palliation due to its high energy beta(-) particle emission [E(beta(max))=1.49 MeV] and is also difficult to produce in large quantities. "
01/01/2006 - "The aim of this article was to review the available literature regarding to the use of strontium-89 in the palliation of osteoblastic bone pain. "

07/01/2020 - "Network meta-analysis for the patients with bone metastases showed that ZA + strontium-89 and ZA harbored significantly clinical benefits than strontium-89 and placebo in terms of 1-year survival rate and SREs. "
04/01/2012 - "Effective use of strontium-89 in osseous metastases."
06/30/2003 - "Strontium-89 in palliative treatement of painfull bone metastases."
03/15/2002 - "Strontium-89 is a palliative agent that acts as a selective radiation source for bone metastasis. "
03/01/1998 - "Palliation of painful bone metastases: Strontium-89."

04/02/1993 - "Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer."
04/01/1998 - "Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. "
01/01/1996 - "Strontium-89 for symptomatic metastatic prostate cancer to bone: recommendations for hospice patients."
01/01/1995 - "Strontium-89 in the management of metastatic prostate cancer."
01/01/2015 - "Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer."

02/01/2000 - "The two patients described in the current study developed AML 17 months and 26 months, respectively, after exposure to strontium-89 for the treatment of prostate carcinoma. "
02/01/2000 - "To the authors' knowledge these patients represent the first two reported cases of AML after strontium-89 therapy for prostate carcinoma. "
07/01/1992 - "Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma."
02/01/2001 - "In conclusion, a PSA response following strontium-89 treatment appears to predict for improved survival in patients with bone metastases from carcinoma of the prostate. "
11/01/1999 - "Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate."

04/02/1993 - "The study was a Phase-III randomized placebo control trial performed in eight Canadian Cancer Centers to evaluate the effectiveness of strontium-89 as an adjunct to local field radiotherapy. "
10/01/2004 - "We studied the correlation between the efficacy of local external beam radiotherapy and the efficacy of strontium-89 in the palliation of osteoblastic metastatic bone pain in 43 patients with cancer. "
02/01/1994 - "Assessment of bone turnover could play a role in the evaluation of response to Strontium-89 used as palliative treatment in symptomatic bone metastases from various primary tumors. "
01/01/2014 - "Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival."
03/01/2001 - "Bone pain palliation with strontium-89 in cancer patients with bone metastases."